Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarction

Victor L. Serebruany, Vladimir V. Yurovsky, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

NPC 15669, a member of the leumedins family, inhibits leukocyte adhesion to the endothelium by blockage of upregulation of a member of β2 integrin family Mac1 (CD11b/CD18). Inhibition of neutrophil-endothelial interactions may alter the course of myocardial reperfusion injury. However, the effects of NPC 15669 supplementation on the hemostatic profile during ischemia- reperfusion are unknown. The aim of the present study was to define changes in the certain hemostatic factors in the natural course of preconditioned myocardial infarction. Twelve consecutive Yorkshire swine underwent myocardial stunning (8 min. left anterior descending artery occlusion followed by 90 min. of reperfusion) and then preconditioned myocardial infarction (50 min. occlusion followed by 3 hours of reperfusion) experiments. NPC 15669 (10 mg/kg loading dose followed by constant infusion at 6 mg·kg-1·h-1) was administered in 6 animals; another 6 swine received saline and served as controls. Blood samples were obtained at baseline, twice during occlusion; and three times during reperfusion. The levels of antithrombin-III, Protein C, total Protein S, fibronectin, endothelin-1, as well as the stable metabolites of thromboxane (TxB2) and prostacyclin (6-keto-PGF(1a)), were determined. NPC 15669 treatment was associated with diminished endothelin-1, TxB2 levels and increased fibronectin, 6-keto-PGF(1a), Protein C and total Protein S concentrations in the setting of preconditioned myocardial infarction. There were no changes in the plasma concentrations of antithrombin-III in NPC 15669 group when compared with controls. The increase in Protein C, total Protein S, and 6- keto-PGF(1a) (favoring antithrombosis), and decrease in endothelin-1 and TxB2 levels (favoring vasodilatation), following NPC 15669 may explain the reduction in infarct size previously reported with this agent.

Original languageEnglish (US)
Pages (from-to)1503-1513
Number of pages11
JournalLife Sciences
Volume65
Issue number14
DOIs
StatePublished - Aug 27 1999

Fingerprint

Hemostatics
Myocardial Infarction
Reperfusion
Protein S
Prostaglandins F
Endothelin-1
Protein C
Antithrombin III
Fibronectins
Swine
Antithrombin Proteins
Myocardial Stunning
Myocardial Reperfusion Injury
Thromboxanes
Epoprostenol
Metabolites
Vasodilation
Integrins
Endothelium
N-(9H-(2,7-dimethylfluoren-9-ylmethoxy)carbonyl)leucine

Keywords

  • Hemostasis
  • Ischemic preconditioning
  • Mac-1 inhibitor
  • Myocardial infarction
  • Swine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarction. / Serebruany, Victor L.; Yurovsky, Vladimir V.; Gurbel, Paul A.

In: Life Sciences, Vol. 65, No. 14, 27.08.1999, p. 1503-1513.

Research output: Contribution to journalArticle

Serebruany, Victor L. ; Yurovsky, Vladimir V. ; Gurbel, Paul A. / Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarction. In: Life Sciences. 1999 ; Vol. 65, No. 14. pp. 1503-1513.
@article{85c404a8a4214a29ad76e54daa8ce235,
title = "Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarction",
abstract = "NPC 15669, a member of the leumedins family, inhibits leukocyte adhesion to the endothelium by blockage of upregulation of a member of β2 integrin family Mac1 (CD11b/CD18). Inhibition of neutrophil-endothelial interactions may alter the course of myocardial reperfusion injury. However, the effects of NPC 15669 supplementation on the hemostatic profile during ischemia- reperfusion are unknown. The aim of the present study was to define changes in the certain hemostatic factors in the natural course of preconditioned myocardial infarction. Twelve consecutive Yorkshire swine underwent myocardial stunning (8 min. left anterior descending artery occlusion followed by 90 min. of reperfusion) and then preconditioned myocardial infarction (50 min. occlusion followed by 3 hours of reperfusion) experiments. NPC 15669 (10 mg/kg loading dose followed by constant infusion at 6 mg·kg-1·h-1) was administered in 6 animals; another 6 swine received saline and served as controls. Blood samples were obtained at baseline, twice during occlusion; and three times during reperfusion. The levels of antithrombin-III, Protein C, total Protein S, fibronectin, endothelin-1, as well as the stable metabolites of thromboxane (TxB2) and prostacyclin (6-keto-PGF(1a)), were determined. NPC 15669 treatment was associated with diminished endothelin-1, TxB2 levels and increased fibronectin, 6-keto-PGF(1a), Protein C and total Protein S concentrations in the setting of preconditioned myocardial infarction. There were no changes in the plasma concentrations of antithrombin-III in NPC 15669 group when compared with controls. The increase in Protein C, total Protein S, and 6- keto-PGF(1a) (favoring antithrombosis), and decrease in endothelin-1 and TxB2 levels (favoring vasodilatation), following NPC 15669 may explain the reduction in infarct size previously reported with this agent.",
keywords = "Hemostasis, Ischemic preconditioning, Mac-1 inhibitor, Myocardial infarction, Swine",
author = "Serebruany, {Victor L.} and Yurovsky, {Vladimir V.} and Gurbel, {Paul A.}",
year = "1999",
month = "8",
day = "27",
doi = "10.1016/S0024-3205(99)00391-4",
language = "English (US)",
volume = "65",
pages = "1503--1513",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "14",

}

TY - JOUR

T1 - Effects of a novel Mac-1 inhibitor, NPC 15669, on hemostatic parameters during preconditioned myocardial infarction

AU - Serebruany, Victor L.

AU - Yurovsky, Vladimir V.

AU - Gurbel, Paul A.

PY - 1999/8/27

Y1 - 1999/8/27

N2 - NPC 15669, a member of the leumedins family, inhibits leukocyte adhesion to the endothelium by blockage of upregulation of a member of β2 integrin family Mac1 (CD11b/CD18). Inhibition of neutrophil-endothelial interactions may alter the course of myocardial reperfusion injury. However, the effects of NPC 15669 supplementation on the hemostatic profile during ischemia- reperfusion are unknown. The aim of the present study was to define changes in the certain hemostatic factors in the natural course of preconditioned myocardial infarction. Twelve consecutive Yorkshire swine underwent myocardial stunning (8 min. left anterior descending artery occlusion followed by 90 min. of reperfusion) and then preconditioned myocardial infarction (50 min. occlusion followed by 3 hours of reperfusion) experiments. NPC 15669 (10 mg/kg loading dose followed by constant infusion at 6 mg·kg-1·h-1) was administered in 6 animals; another 6 swine received saline and served as controls. Blood samples were obtained at baseline, twice during occlusion; and three times during reperfusion. The levels of antithrombin-III, Protein C, total Protein S, fibronectin, endothelin-1, as well as the stable metabolites of thromboxane (TxB2) and prostacyclin (6-keto-PGF(1a)), were determined. NPC 15669 treatment was associated with diminished endothelin-1, TxB2 levels and increased fibronectin, 6-keto-PGF(1a), Protein C and total Protein S concentrations in the setting of preconditioned myocardial infarction. There were no changes in the plasma concentrations of antithrombin-III in NPC 15669 group when compared with controls. The increase in Protein C, total Protein S, and 6- keto-PGF(1a) (favoring antithrombosis), and decrease in endothelin-1 and TxB2 levels (favoring vasodilatation), following NPC 15669 may explain the reduction in infarct size previously reported with this agent.

AB - NPC 15669, a member of the leumedins family, inhibits leukocyte adhesion to the endothelium by blockage of upregulation of a member of β2 integrin family Mac1 (CD11b/CD18). Inhibition of neutrophil-endothelial interactions may alter the course of myocardial reperfusion injury. However, the effects of NPC 15669 supplementation on the hemostatic profile during ischemia- reperfusion are unknown. The aim of the present study was to define changes in the certain hemostatic factors in the natural course of preconditioned myocardial infarction. Twelve consecutive Yorkshire swine underwent myocardial stunning (8 min. left anterior descending artery occlusion followed by 90 min. of reperfusion) and then preconditioned myocardial infarction (50 min. occlusion followed by 3 hours of reperfusion) experiments. NPC 15669 (10 mg/kg loading dose followed by constant infusion at 6 mg·kg-1·h-1) was administered in 6 animals; another 6 swine received saline and served as controls. Blood samples were obtained at baseline, twice during occlusion; and three times during reperfusion. The levels of antithrombin-III, Protein C, total Protein S, fibronectin, endothelin-1, as well as the stable metabolites of thromboxane (TxB2) and prostacyclin (6-keto-PGF(1a)), were determined. NPC 15669 treatment was associated with diminished endothelin-1, TxB2 levels and increased fibronectin, 6-keto-PGF(1a), Protein C and total Protein S concentrations in the setting of preconditioned myocardial infarction. There were no changes in the plasma concentrations of antithrombin-III in NPC 15669 group when compared with controls. The increase in Protein C, total Protein S, and 6- keto-PGF(1a) (favoring antithrombosis), and decrease in endothelin-1 and TxB2 levels (favoring vasodilatation), following NPC 15669 may explain the reduction in infarct size previously reported with this agent.

KW - Hemostasis

KW - Ischemic preconditioning

KW - Mac-1 inhibitor

KW - Myocardial infarction

KW - Swine

UR - http://www.scopus.com/inward/record.url?scp=0033610081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033610081&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(99)00391-4

DO - 10.1016/S0024-3205(99)00391-4

M3 - Article

C2 - 10530802

AN - SCOPUS:0033610081

VL - 65

SP - 1503

EP - 1513

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 14

ER -